Eterna Therapeutics Inc ERNA

$0.23 -0.02 (-6.24%)

Valuation

Market cap
1,431,000
Revenue TTM
$580,000
Net income TTM
$-44,540,000
PE ratio
0.00
Forward PE
—
Profit margin
-7,679.31%
Debt to equity
0.00

Trading

Volume
359,085
Avg volume
12,707,749
Day's range
$0.22 – $0.24
Shares out
5,411,000
Stochastic %K
48%
Beta
4.47
Analysts
Hold
Price target
—

Price

Company profile

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rhe...

Show more

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 798 6700
Website
https://www.ernexatx.com
Address
1035 Cambridge Street, Suite 18A, Cambridge, United States

Latest news

Stocktwits

Ernexatx Oct 6, 1:12 PM
$ERNA ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center https://www.globenewswire.com/news-release/2026/10/06/3375526/0/en/ernexa-therapeutics-erna-101-selected-for-flash-talk-presentation-at-nature-conferences-next-generation-cancer-therapeutics-meeting-co-hosted-by-md-anderson-cancer-center.html
0 replies
2pumps1dump Oct 3, 8:43 PM
$ERNA IND inbound, need to add this week 👌🏽
1 replies
Victory777777 Oct 2, 12:10 PM
$AMOD top 🔝 1 Keep running $AIXI $AMOD $ERNA $NIVF $SDEV
0 replies
AlertsAndNews Oct 2, 12:09 PM
Good morning and happy Friday Gappers this morning include $AMOD $NIVF $SDEV $AIXI $ERNA Lets get it!
0 replies
Ernexatx Oct 1, 5:58 PM
$ERNA CEO Sanjeev Luther discusses Dr. Robert J. Spiegel’s Board appointment and how his oncology expertise strengthens Ernexa as ERNA-101 advances toward the clinic. Watch the CEO Corner: https://vimeo.com/1231765890/f88650fc78
0 replies
Ernexatx Oct 1, 1:30 PM
$ERNA CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic https://www.globenewswire.com/news-release/2026/10/01/3373011/0/en/ernexa-therapeutics-ceo-corner-highlights-appointment-of-dr-robert-j-spiegel-as-company-sharpens-oncology-focus-and-advances-erna-101-toward-the-clinic.html
0 replies
Ernexatx Sep 30, 12:59 PM
$ERNA Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND https://www.globenewswire.com/news-release/2026/09/30/3371881/0/en/ernexa-therapeutics-reports-compelling-erna-101-safety-results-across-three-critical-ind-enabling-studies-advancing-toward-planned-q4-2026-ind.html
0 replies
2pumps1dump Sep 30, 12:33 PM
$ERNA has news 🗞️
0 replies